Emerging Europe
Emerging Europe Pharmaceuticals & Healthcare Insight provides country-by-country analysis of the key trends impacting the prescription, OTC and generic drugs industries across Emerging Europe. Emerging Europe Pharmaceuticals & Healthcare Insight includes competitive intelligence on the growth strategies of leading national and multinational companies, along with 5-year industry forecasts for each country. The service includes access to the very latest analysis, a searchable archive of articles and data and the ability to download PDFs of current and back issues.
›› To gain FREE online access for 14 days and to download a FREE PDF, click trial.
›› To receive 15 monthly pdf issues for the price of 12 and to gain immediate online access, click subscribe.
Russia / Industry
The Federal Antimonopoly Service's decision, to block a proposed merger between Abbott Laboratories Petrovax Pharm, while unexpected, does not signal a worsening investment climate in Russia. The country's proximity to the Asia-Pacific region, and seasonal flu pandemics, have influenced the FAS's desire to protect vaccine production in Russia. We note that there is a strong precedence...
2013-04-22Ukraine / Industry
BMI View: The announcement by the health minister that compulsory health insurance is unlikely to be rolled out in the short term is disappointing but not unexpected, given the country's...
2013-04-10Ukraine / Industry
BMI View: Although largely regressive, the impact of the government's move to limit medicine procurement to domestic production will be low, given the small scale of state drug expenditure...
2013-04-09Industry Developments
Russia
The Federal Antimonopoly Service's decision, to block a proposed merger between Abbott Laboratories Petrovax Pharm, while unexpected, does not signal a worsening investment climate...
2013-04-22Ukraine
BMI View: The announcement by the health minister that compulsory health insurance is unlikely to be rolled out in the short term is disappointing but not unexpected, given the country's...
2013-04-10Ukraine
BMI View: Although largely regressive, the impact of the government's move to limit medicine procurement to domestic production will be low, given the small scale of state drug expenditure...
2013-04-09BMI View: With the exception of Kazakhstan, the Central Asian republics remain largely insular. The significant barriers to entry for multinational drugmakers and the level of state...
2013-04-08
